High levels of latent antithrombin in plasma from patients with antithrombin deficiency

Thrombosis and Haemostasis

Volumn 117, Issue 5, 2017, Pages 880-888

  de la Morena Barrio, María ^a,b   Sandoval, Edna ^c   Llamas, Pilar ^d   Wypasek, Ewa ^e,f   Toderici, Mara ^a   Navarro Fernández, José ^a   Rodríguez Alen, Agustin ^c   Revilla, Nuria ^a   López Gálvez, Raquel ^a   Miñano, Antonia ^a   Padilla, José ^a   de la Morena Barrio, Belén ^a   Cuesta, Jorge ^c   Corral, Javier ^a,b   Vicente, Vicente ^a,b  

^a HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^e Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^f JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antithrombin; Gene mutations; Latent; Thrombosis

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; BIOLOGICAL MARKER; SERPINC1 PROTEIN, HUMAN;

ADULT; ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HETEROZYGOSITY; HUMAN; HUMAN CELL; IMMUNODIFFUSION; MAJOR CLINICAL STUDY; MALE; MODEL; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PLEIOTROPY; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; SERPINC1 GENE; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; AGED; BLOOD; BLOOD CLOTTING; CASE CONTROL STUDY; CHEMISTRY; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MOLECULAR MODEL; MUTATION; NEWBORN; PHENOTYPE; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION; TEMPERATURE; UPREGULATION; VEIN THROMBOSIS;

ADULT; AGED; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; BIOMARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; CHILD; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; PHENOTYPE; PROTEIN CONFORMATION; PROTEIN STABILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE; UP-REGULATION; VENOUS THROMBOSIS;

EID: 85019587786     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-11-0866     Document Type: Article

References (37)

1. Bjork I, Olson ST. Antithrombin. A bloody important serpin. Adv Exp Med Biol 1997; 425: 17-33.
2. Aguila S, Navarro-Fernandez J, Bohdan N, et al. Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations. J Thromb Haemost 2014; 12: 1131-1140.
3. Lane DA, Olds RJ, Conard J, et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90: 2422-2433.
4. Lane DA, Olds RJ, Boisclair M, et al. Antithrombin III mutation database: first update. For the Thrombin and its Inhibitors Subcommittee of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1993; 70: 361-369.
5. Huntington JA. Serpin structure, function and dysfunction. J Thromb Haemost 2011; 9 (Suppl 1): 26-34.
6. Whisstock JC, Bottomley SP. Molecular gymnastics: serpin structure, folding and misfolding. Curr Opin Struct Biol 2006; 16: 761-768.
7. Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol 1995; 2: 96-113.
8. Roussel BD, Irving JA, Ekeowa UI, et al. Unravelling the twists and turns of the serpinopathies. FEBS J 2011; 278: 3859-3867.
9. Carrell RW, Stein PE, Fermi G, et al. Biological implications of a 3 A structure of dimeric antithrombin. Structure 1994; 2: 257-270.
10. Mushunje A, Evans G, Brennan SO, et al. Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost 2004; 2: 2170-2177.
11. Larsson H, Sjoblom T, Dixelius J, et al. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res 2000; 60: 6723-6729.
12. O’Reilly MS, Pirie-Shepherd S, Lane WS, et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-1928.
13. Zhang W, Chuang YJ, Swanson R, et al. Antiangiogenic antithrombin downregulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood 2004; 103: 1185-1191.
14. Beauchamp NJ, Pike RN, Daly M, et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998; 92: 2696-2706.
15. Bruce D, Perry DJ, Borg JY, et al. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp). J Clin Invest 1994; 94: 2265-2274.
16. Corral J, Hernandez-Espinosa D, Soria JM, et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
17. Corral J, Rivera J, Martinez C, et al. Detection of conformational transformation of antithrombin in blood with crossed immunoelectrophoresis: new application for a classical method. J Lab Clin Med 2003; 142: 298-305.
18. delaMorena-Barrio ME, Anton AI, Martinez-Martinez I, et al. Regulatory regions of SERPINC1 gene: Identification of the first mutation associated with antithrombin deficiency. Thromb Haemost 2012; 107: 430-437.
19. Martinez-Martinez I, Ordonez A, Navarro-Fernandez J, et al. Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica 2010; 95: 1358-1365.
20. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997; 18: 2714-2723.
21. Zhou A, Huntington JAand Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94: 3388-3396.
22. Chang JY, Tran TH. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem 1986; 261: 1174-1176.
23. Picard V, Bura A, Emmerich J, et al. Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. Br J Haematol 2000; 110: 731-734.
24. Millar DS, Wacey AI, Ribando J, et al. Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Hum Genet 1994; 94: 509-512.
25. Irving JA, Pike RN, Lesk AM, et al. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res 2000; 10: 1845-1864.
26. Olds RJ, Lane DA, Caso R, et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood 1992; 79: 1206-1212.
27. Sas G, Blasko G, Banhegyi D, et al. Abnormal antithrombin III (antithrombin III „Budapest“) as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32: 105-115.
28. Bock SC, Marrinan JA and Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988; 29: 6171-6178.
29. Picard V, Nowak-Gottl U, Biron-Andreani C, et al. Molecular bases of antithrombin deficiency: twenty-two novel mutations in the antithrombin gene. Hum Mutat 2006; 27: 600.
30. Luxembourg B, Delev D, Geisen C, et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
31. Navarro-Fernandez J, delaMorena-Barrio ME, Padilla J, Miñano A, Bohdan N, Aguila S, et al. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate risk of thrombosis that causes a transient antithrombin deficiency. Thromb Haemost. In press 2016.
32. Corral J, Vicente Vand Carrell RW. Thrombosis as a conformational disease. Haematologica 2005; 90: 238-246.
33. Corral J, Huntington JA, Gonzalez-Conejero R, et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost 2004; 2: 931-939.
34. Quinsey NS, Fitton HL, Coughlin P, et al. Introduction of a mutation in the shutter region of antithrombin (Phe77--> Leu) increases affinity for heparin and decreases thermal stability. Biochemistry 2003; 42: 10169-10173.
35. Chandrasekhar K, Ke H, Wang N, et al. Cellular folding pathway of a metastable serpin. Proc Natl Acad Sci USA 2016; 113: 6484-6489.
36. Yamasaki M, Li W, Johnson DJ, et al. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerisation. Nature 2008; 455: 1255-1258.
37. Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 2011; 122: 1-6.